WEDNESDAY, March 21 (HealthDay News) -- A new anti-cholesterol
drug appears safe and effective in people already taking statins
such as Lipitor, making it a potential addition to statin therapy
or an alternative, a preliminary new study suggests.
Two single-dose trials in healthy volunteers and a multiple-dose
trial in a group with high cholesterol showed that the drug, known
as a monoclonal antibody, reduced low-density lipoprotein (LDL, or
"bad") cholesterol levels an average of 40 percent. The injectable
drug was also well-tolerated by all participants, with headache the
most commonly reported side effect.
The drug works by attacking a destructive enzyme in the liver,
keeping LDL cholesterol from spilling into the bloodstream,
according to the report published in the March 22 issue of the
New England Journal of Medicine.
"It was entirely safe, as best they could tell, and LDL levels plummeted within a matter of a few days and remained low for three months," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City, who was not involved in the study. "If this antibody turns out to be as safe and effective as it appears, this may very well be a very important method for controlling LDL cholesterol, particularly in patients with [drug-resistant] cases."
The study, by Dr. Evan Stein, of the Metabolic and
Atherosclerosis Research Center in Cincinnati, and colleagues, was
funded by Sanofi and Regeneron Pharmaceuticals -- makers of the
About one in four Americans aged 45 and older takes statins,
which interfere with the production of cholesterol in the liver, to
control their high cholesterol levels and improve their odds
against heart disease, according to the U.S. Centers for Disease
Control and Prevention. While widely effective, some patients
experience intolerable side effects -- which include liver damage
or muscle pain -- and others don't achieve the recommended LDL
blood levels of 70 milligrams (mg) per deciliter or lower for those
at risk of heart disease.
Two randomized, single-dose studies of the antibody, known as
REGN727, were administered either intravenously (in 40
participants) or by injection (in 32 participants) and compared
with a group given an inactive placebo. These trials were followed
by a randomized study of multiple doses in 51 adults with high
cholesterol who were taking atorvastatin (brand name Lipitor) and
whose baseline LDL levels were more than 100 mg per deciliter.
Higher doses of REGN727 lowered LDL cholesterol levels by up to
64 percent, and the effect was similar across the board whether or
not participants were also taking a statin, which works by a
Commenting on the study, Christine Metz, head of the Laboratory
of Medicinal Biochemistry at the Feinstein Institute for Medical
Research in Manhasset, N.Y., said, "The next step would be to test
a much larger group of people for a much longer time. But this is
very promising, apparently safe under the conditions used, and
worth very quickly going forward."
Garratt noted that the new drug, which could take at least
several years to reach the market, would need to be injected, since
antibodies typically can't be formulated into pills. Such a
compound would likely be extremely expensive, especially when
compared to statins, which are now available as generic drugs.
Also, like statins, such a drug would probably need to be taken for
life, he said.
Metz pointed out that the trials were very small and consisted
heavily of men, making it hard to generalize results for a broader
However, "I thought the study was very beautifully conceived and
well done," she added. "It did everything it set out to do."
The U.S. National Library of Medicine has more information about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.